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ABSTRACT:  Understanding antigen-antibody interactions is important to many emerging medical and bioanalytical applications. 
In particular, the levels of antigen expression at the cell surface may determine antibody-mediated cell death. This parameter has a 
clear effect on outcome in patients undergoing immunotherapy. In this context, CD20 which is expressed in the membrane of B 
cells has received significant attention as target for immunotherapy of leukemia and lymphoma using the monoclonal antibody 
rituximab. To systematically study the impact of CD20 density on antibody recognition, we designed self-assembled monolayers 
that display tunable CD20 epitope densities. For this purpose, we developed in situ click chemistry to functionalize SPR sensor 
chips. We find that the rituximab binding affinity depends sensitively and non-monotonously on CD20 surface density. Strongest 
binding, with an equilibrium dissociation constant (KD = 32 nM) close to values previously reported from in vitro analysis with B 
cells (apparent KD between 5 and 19 nM), was obtained for an average inter-antigen spacing of 2 nm. This distance is required for 
improving rituximab recognition, and in agreement with the known requirement of CD20 to form clusters to elicit a biological 
response. More generally, this study offers an interesting outlook in the understanding of the necessity of epitope clusters for effec-
tive mAb recognition. 
Despite the continuous improvement of traditional chemo-
therapy, the use of monoclonal antibodies (mAbs) as drugs for 
the treatment of a variety of diseases has been growing steadi-
ly for the last two decades.1 In this context, there is a strong 
interest in studying mAb recognition of cognate antigens. 
MAbs are used in oncology for many therapeutic targets in-
cluding the CD20 antigen, the human epidermal growth factor 
receptor 2 (HER2), the vascular endothelial growth factor 
(VEGF), the epidermal growth factor receptor (EGFR) and the 
programmed cell death protein 1 (PD-1).2 The hematopoietic 
differentiation antigens associated with cluster of differentia-
tion (CD) represent the main targets for mAb in oncology.3 In 
particular, the CD20 antigen is the target of several therapeutic 
mAbs and their derivatives (e.g. rituximab, ibritumomab, 
ofatumumab, obinutuzumab, ocrelizumab) that are successful-
ly used to treat B-cell malignancies, including non-Hodgkin’s 
lymphoma and chronic lymphocytic leukemia, as well as some 
autoimmune disorders such as rheumatoid arthritis, systemic 
lupus erythematosus and multiple sclerosis.4 
The antigen-binding activity of mAbs determines their bio-
logical efficacy and depends on several factors, including 
antigen density, association and dissociation rates. Several 
studies have suggested that the increase of CD20 antigen 
expression modulates the biological response of mAbs such as 
complement-dependent cytotoxicity (CDC) and antibody-
dependent cellular cytotoxicity (ADCC) that trigger cell 
death.5,6,7 As the antigen distribution generally has a direct 
impact on the clinical efficacies of mAbs, it is of interest to 
study the influence of CD20 density on mAb recognition. 
CD20-rituximab (RTX) interactions have been studied in vitro 
on B-cell lymphoma lines by using flow cytometry or gamma 
counter experiments.8,9 Equilibrium dissociation constants 
(KD) in the nanomolar range (5-19 nM) have been reported. 
These studies, however, did not assess the antigen surface 
density and distribution. Consequently, it remains unknown 
how RTX binding to CD20 depends on CD20 surface density, 
and if the measured dissociation constants are representative 
of high or low CD20 densities. To date, such information is 
rarely available for any mAb/antigen combination of clinical 
relevance highlighting the need for new methods to character-
ize how mAb recognition depends on antigen density. 
Label-free solid-phase interaction assays with highly de-
fined biofunctional surfaces can overcome the limitations of 
cell-based assays, and enable quantitate antigen-antibody 
interaction analysis. Initial kinetic studies concerning CD20-
RTX interactions performed by SPR analysis have shown 
important variation of the equilibrium dissociation constants 
(KD) values, spanning from a few hundred nanomolar to sever-
al micromolar.10,11 The disparity in KD values reported for 
solid-phase versus cell-based binding assays could be related 
to differences in the accessibility of the immobilized CD20 
epitope. In particular, commercial SPR sensors rely on the 
engrafting of the antigen within a three-dimensional (albeit 
thin) hydrogel matrix which may impose steric constraints to 
mAb binding. CD20 as a trans-membrane protein is well-
oriented on the cell surface, and one can expect to improve 
recognition if this two-dimensional antigen presentation was 
reproduced in SPR assays. 
 
A number of strategies have been reported to immobilize 
peptide probes onto gold surfaces (as required for SPR) for 
designing peptide-microarrays 12 or peptide-based biosen-
sors.13 These involve the direct adsorption of thiolated pep-
tides (by the way of cysteine) 14,15 or a covalent coupling of the 
peptide to preformed self-assembled monolayers (SAMs) of 
alkanethiols previously adsorbed on the gold substrate. For the 
latter purpose, Cu(I)-catalyzed azide-alkyne cycloaddition 
(CuAAC) has been demonstrated to be well suited for the 
chemical grafting of peptides onto surfaces via an azide-
displaying SAM.16-19 This chemoselective ligation is generally 
characterized by quantitative yields and fast reaction kinetics. 
In addition, the triazole moiety generated by the reaction be-
tween azide and alkyne was shown to be remarkably inert 
resulting in a chemically highly stable peptide-functionalized 
surface. 
In the present work, we have examined the dependence of 
the binding affinity of RTX on CD20 epitope surface density, 
which is known to be a critical point for the therapeutic re-
sponse. To this end, the characterization of the peptide func-
tionalized-surface and the binding assays were achieved by 
using surface sensitive techniques such as quartz crystal mi-
crobalance (QCM-D) and surface plasmon resonance (SPR). 
These label-free detection techniques provide quantitative 
information on the amount of CD20 peptide grafted on the 
SAM gold substrate, and also kinetic and thermodynamic 
parameters of the binding events between CD20-
functionalized surfaces and RTX. 
All organic compounds were purchased from VWR Interna-
tional S.A.S. (Fontenay-sous-Bois, France), Sigma-Aldrich 
(Saint-Quentin Fallavier, France), unless otherwise specified 
in the text. Rituximab (MabThera) was provided gracefully by 
Genentech, Inc. (San Francisco, US). Solution of infusion was 
provided at a concentration of 10 mg/mL (i.e. 69.5 µM). 
Synthesis of CD20 epitope and CD20 scramble. The CD20 
peptide used in this study corresponds to a 25-amino-acid 
sequence that is located in the extracellular part of the full 
CD20 protein. The CD20 scramble peptide used as a reference 
was composed of the same amino-acids in a distinct order. The 
CD20 and CD20 scramble sequences are 
NIYNCEPANPSEKNSPSTQYCYSIQ and 
SATNCNSEYQNEPNYIPYSQCKPIS respectively. Whilst 
both sequences possess a C5-C21 disulfide bridge, all other 
peptides were in a randomly selected order for the CD20 
scramble. Synthesis of the protected peptides was carried out 
using the Fmoc/t-Bu strategy on a peptide synthesizer (Syro2, 
Biotage) using 2-chlorotritylchloride®. Reaction with 4-
pentynoic acid was performed on the resin to incorporate the 
alkyne function at the N-terminus. After cleavage and removal 
of protecting groups, formation of disulfide bridges was per-
formed under oxidative conditions. Peptides were then puri-
fied by RP-HPLC and their concentration quantified by a UV 
spectrophotometer (See the supporting information). 
QCM-D measurements. Measurements were performed with 
a Q-Sense E4 system equipped with 4 independent flow mod-
ules (Biolin Scientific, Västra Frölunda, Sweden). The system 
was operated in flow mode with a flow rate of typically 10 
μL/min using a peristaltic pump (ISM935C, Ismatec, Zurich, 
Switzerland). The working temperature was 25°C. Frequency 
shifts Δf and dissipation shifts ΔD were measured at six over-
tones (n = 3, 5, 7, 9, 11, 13), corresponding to resonance fre-
quencies of fn ≈ 5, 15, 25, 35, 45, 55, 65 MHz; changes in 
dissipation and normalized frequency, Δf = Δfn/n, of the sev-
enth overtone (n = 7) are presented. Any other overtone would 
have provided comparable information. 
Surface preparation. Prior to each QCM-D measurement, 
QCM-D sensors were cleaned by rinsing with ultrapure water, 
blow-drying with N2 and exposure to UV/ozone (Jelight, Ir-
vine, CA, USA) for 10 min. Within 5 min after UV/ozone 
treatment, the sensors were immersed in an ethanolic solution 
of HS-(CH2)11-(EG)6-N3 and HS-(CH2)11-(EG)6-OH 
(ProChimia Surface, Poland), at a total concentration of 1 mM 
and the desired molar ratio of thiol-azide to thiol-hydroxyle. 
After overnight incubation, the sensor surfaces were rinsed 
with ethanol and blow-dried with N2 gas, before being in-
stalled in the QCM-D modules. 
Monitoring of the covalent peptide grafting and binding 
assays using QCM-D. For the covalent peptide grafting, 
ultrapure water was first injected in the measurement chamber 
until reaching a stable baseline. DMSO:H2O (1:1) as running 
solution was then injected at a standard flow rate of 10 
μL/min. Degassed solutions were injected in the measurement 
chambers, including CD20 alkyne/CD20-scramble alkyne 
(200 µM), CuSO4 (500 µM), Tris[(1-benzyl-1H-1,2,3-triazol-
4-yl)methyl]amine (TBTA) (500 µM), and (+)-sodium L-
ascorbate (3 mM). After reaching the plateau, the sensor sur-
faces were rinsed with DMSO:H2O (1:1). For the binding 
assay, functionalized surfaces were incubated in PBS (1×), 
citrate (3 mM) and P80 (0.005%) running buffer. Rituximab 
was then injected in QCM-D module at various concentrations 
in PBS. The sensor surfaces were rinsed after reaching the 
plateau. For binding assays carried out for determining the KD, 
30 s injections of Glycine-HCl (10 mM, pH 2) were performed 
between each RTX concentration. 
SPR analysis. SPR data were obtained on a Biacore T200 (GE 
Healthcare). Measurements were performed on gold surfaces. 
Sensor chips were cleaned by UV-ozone treatment during 10 
min after being rinsed with ultrapure water and ethanol. The 
cleaned gold surfaces were then functionalized according to 
the following procedure. Firstly, mixed self-assembled mono-
layers (SAMs) were formed at room temperature by immers-
ing gold-coated sensors overnight in a thiol mixture of varying 
percentages of HS-(CH2)11-EG6-N3 and HS-(CH2)11-EG4-OH 
(1 mM total thiol concentration in EtOH). Sensor chips were 
rinsed with ethanol and blow-dried with nitrogen gas. The 
surfaces were then inserted in the Biacore T200 device. For 
the grafting of CD20 antigen, manual runs were conducted 
with water as running solvent at 2 µL/min. 
The azide-alkyne cycloaddition permitted the covalent graft-
ing of CD20 scramble on channel 1 for the reference, and 
CD20 on channel 2. Degassed solutions injected are composed 
of CD20 alkyne/CD20-scramble alkyne (200 µM), CuSO4 
(500 µM), Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
(TBTA) (500 µM), and (+)-sodium L-ascorbate (3 mM), in 
DMSO:H2O (1:1). Because the microfluidic system is sensi-
tive to high concentrations of DMSO, the time of injection 
was controlled and optimized at 8 min for each channel, with a 
8 min wait between each injection. The large change of solu-
tion refractive index during the injection prevents monitoring 
of the grafting process in real-time. However, the quantity of 
immobilized antigen could be evaluated by comparing the 
 
shifts in resonance units before and after the injection (Fig. S1 
in the supporting information). 
The SPR-Biacore experimental conditions were optimized 
concerning on the one hand the tethering of CD20 (especially 
the incubation time of CuAAC reactants dissolved in 
H2O:DMSO mixture) and on the other hand the composition 
of the buffer for RTX binding assays (Fig. S3 in the support-
ing information). The optimized running buffer (RB) consisted 
of PBS (1×), citrate (3 mM) and polysorbate P80 (0.005%). 
Flow cell 1 was functionalized with CD20 scramble to provide 
a reference surface. Binding assays were conducted using a 
flow rate of 30 μL/min at 25°C. The stability of the CD20-
functionalized surface was also been checked by achieving 
tests of repeatability of RTX binding on CD20-functionalized 
flow-cells (Fig. S5 in the supporting information). RTX dis-
solved in RB was injected at different concentrations using the 
high performance method (injection time: 4 min, stabilization 
time: 10 min). The RTX concentrations investigated are the 
following: 5, 10, 20, 50, 100, 200, 500, 1000 nM. A regenera-
tion step was necessary between each RTX injection, and was 
performed by injecting a solution of Glycine-HCl (10 mM, pH 
2) for 10 s. Prior to curve fitting analysis, the binding sensor-
grams were double-referenced using reference flow cell 1 and 
preceding buffer blank subtractions to remove the non-specific 
adsorption of RTX and the change in refractive index respec-
tively. The binding rate constants of CD20/RTX interactions 
were calculated by a nonlinear analysis of the association and 
dissociation phases using the SPR kinetic evaluation software 
of Biacore T200 (evaluation Software 2.0.1). The data were 
fitted using a heterogeneous ligand model, which provides the 
best fitting (Fig. S6 in the supporting information). The re-
ported values are the average of representative independent 
experiments and the errors provided are standard deviations 
from the mean. Each SPR experiment was repeated at least 
four times.  
Fab generation. RTX Fab fragments were generated from 
papain digestion of the mAb by using the Pierce Fab prepara-
tion kit (Thermo Scientific) and following the given instruc-
tions. Fab fragments were then purified with column provided 
by the kit. The digestion was checked by SDS-PAGE (Fig. S8 
in the supporting information), and Fab fragments concentra-
tion was measured by UV. 
Control and characterization of CD20 density on gold 
substrates. We used the extracellular loop of the CD20 pro-
tein (amino acids N163 to Q187) which is known to be the 
binding epitope of RTX.20 This peptide was prepared by clas-
sical solid-phase peptide synthesis and a disulfide bridge for-
mation in buffered solution (see the supporting information). 
We introduced an alkyne function at the N-terminus for Cu-
AAC coupling to preformed SAM surfaces displaying azide 
groups (Fig. 1), as previously described.21,22 Thanks to this 
site-specific ligation, and the disulfide bridge present in the 
natural peptide sequence, the CD20 epitope is displayed with a 
defined orientation and conformation that recapitulates the 
presentation of the extracellular CD20 loop on the cell sur-
face.20 The SAM contained alkanethiolates with terminal-
oligo(ethyleneglycol) (OEG) that provides physical rigidity in 
combination with chemical flexibility. Moreover, the OEG-
alkanethiols form a bioinert background conferring resistance 
to non-specific protein adsorption.23 The SAMs presenting 
azide were adsorbed on gold substrates by incubating thiol 
solutions with varying molar ratios of HS-(CH2)11-(EG)6-N3 
(thiol-azide) and HS-(CH2)11-(EG)4-OH (thiol-hydroxyle). By 
using thiol-azide fractions ranging from 0.1% to 50%, we 
were able to design functional surfaces with tunable coverages 
of the CD20 epitope (Fig. 1, Fig S2 in the supporting infor-
mation). 
 
Figure 1. Schematic representation of the CD20 epitopes grafting 
onto a preformed SAM-azide by CuAAC. The disulfide bridge is 
shown in red. 
In order to control the CD20 surface coverage, two mass-
sensitive surface techniques, QCM-D and SPR, were em-
ployed. While no measurable change in QCM-D signals (i.e. 
shifts in frequency, f, and dissipation, D) was recorded during 
the injection of CD20 solution without the CuAAC reactants 
in the flow chamber, a fast decrease in frequency was ob-
served when the reaction mixture containing the CD20 epitope 
was injected, indicating covalent grafting of CD20 to the 
SAM-gold substrate (Fig. S9-S10 in the supporting infor-
mation). Rinsing with pure solvent led to stable signals show-
ing the stability of CD20-functionalized surfaces, and thus 
providing further evidence of the chemical grafting of the 
peptide to the surface. The QCM-D traces showed only small 
shifts in dissipation after CD20-functionalization, indicating 
that the CD20 epitope form a relatively rigid film. The Sauer-
brey relation (Eq. S2) can thus be applied for the determina-
tion of the acoustic mass (mQCM; Table 1). QCM-D provides 
hydrated masses (mass of CD20 layer with hydrodynamically 
coupled water) which show increasing values until reaching a 
maximum at 432 ng/cm2 for 12.5% of thiol-azide. 
Following the procedure as established by QCM-D, the co-
valent grafting of CD20 was transferred to SPR sensors. Graft-
ing was carried out inside the Biacore apparatus onto SAM-
functionalized sensor chips, as this enabled different meas-
urement channels to be functionalized with various peptides. 
In particular, a scramble containing the same amino acids as 
the CD20 peptide but in a different random order was chosen 
as reference to be able to correct for variations in the solution 
refractive index and/or spurious non-specific interactions. 
To the best of our knowledge, there are very few examples 
of in situ grafting of SPR sensor chips through CuAAC using 
an SPR apparatus equipped with a microfluidic system.24 To 
prevent damage to the microfluidic system, the hydro-organic 
solution (H2O/DMSO) containing the click chemistry reactants 
was injected only for a short time (8 min) in the flow cells 
(Fig. S1 in the supporting information). An additional benefit 
of the in situ click chemistry is that it allows quantitating the 
 
amount of grafted CD20 from the change in the SPR signal. 
By using Jung’s formula (Eq. S1 in the supporting infor-
mation) the magnitude of the response units (RU) was con-
verted into areal mass densities. Jung’s formula requires the 
SAM and CD20 to be considered as separate layers, and the 
layer thicknesses to be known. These were measured by spec-
troscopic ellipsometry (SE) (See the supporting information). 
Whatever the azide percentage, the thickness of the SAM was 
found to be of 2.5 ± 0.5 nm, in accordance with previous re-
sults (2.6 nm).25 After CD20 grafting at saturation, an addi-
tional film thickness of 4.6 ± 0.2 nm was found. The areal 
mass densities of CD20 calculated from SPR experiments 
show that the immobilization capacity of the SAM-azide sub-
strate increases monotonously with the number of azide reac-
tive functions across the probed range from 0 to 50% of thiol-
azide (Table 1). A comparison of the areal mass densities 
measured by QCM-D (mQCM; hydrated mass) and by SPR 
(mSPR; dry mass) provides a measure of the CD20 film hydra-
tion (Eq. S3 in the supporting information): the hydration is 
high (92%) for low CD20 density (2.8 pmol.cm-2 correspond-
ing to mSPR of 8 ng.cm-2) and decreases for denser CD20 lay-
ers, down to 38% at 85 pmol.cm-2 (mSPR = 249 ng.cm-2).  The 
decrease of coupled water induced by lowering the surface 
coverage as sensed by QCM-D has ever been reported and 
modeled for globular proteins.26 The authors showed that the 
hydration curves could be well fitted by a straight line by 
using a model that ascribed a hydration coat (truncated pyra-
mid-shaped) to each adsorbed biomolecule. Furthermore, we 
noticed that to reach a CD20 surface density of 46 pmol.cm-2 
(mSPR = 135 ng.cm-2) only 6% of azide-presenting alkanethiols 
would be required in the SAM (since total alkanethiol surface 
density is 7.3 10-10 mol.cm-2).22 The mismatch with the 12.5% 
thiol-azide used in the solution to prepare the SAMs is likely 
due in part to preferential binding of the thiol-hydroxyl, as 
previously reported.22 Additionally, for high thiol-azide densi-
ties, the CuAAC reaction may be incomplete due to steric 
hindrance of CD20 on surface. 
Assuming a random distribution of CD20 epitopes on the 
SAM surface, root-mean-square (rms) distances between 
adjacent CD20 epitopes were calculated based on the SPR 
data. Values ranging from 9.1 to 1.4 nm were obtained for 
surfaces prepared with thiol-azide fractions ranging from 0.1% 
to 50%, respectively (Table 2). 


















0.1 nd nd 60 ± 11 6 ± 1 nd 
1 5.6 ± 0.2 100 ± 4 82 ± 22 8 ± 2 92 ± 2 
2.5 14 ± 2.0 251 ± 3 694 ± 118 69 ± 12 72 ± 1 
12.5 24 ± 1.0 432 ± 9 1352 ± 308 135 ± 31 69 ± 7 
20 23.4 ± 1.3 421 ± 23 1642 ± 381 164 ± 38 61 ± 7 
50 22.4 ± 0.6 404 ± 11 2488 ± 145 249 ± 14 38 ± 2 
nd = not determinated. (a) Acoustic mass determined with Sauer-
brey equation and 7th overtone. (b) SPR Response corresponding 
to the change of baseline magnitude before and after grafting. (c) 
Optical mass calculated following Jung’s formula (Eq. S1 in the 
supporting information). 
Effect of CD20 density on rituximab recognition. The spec-
ificity of the resulting CD20 functionalized surface towards 
RTX binding affinity was again evaluated by QCM-D and 
SPR. Using QCM-D, a comparison of two functionalized-
surfaces displaying the CD20 epitope and the CD20 scramble 
respectively clearly demonstrated successful and fully selec-
tive binding of RTX (10 nM) to CD20 (Fig. S9 in the support-
ing information). Additional SPR experiments were carried 
out to confirm the specificity of the recognition event. Injec-
tion of RTX (at 1 μM) to a surface presenting the CD20 
epitope led to a response of 1800 RU, whereas only 100 RU 
were measured with the CD20 scramble and 60 RU with a 
pure and inert alkanethiolate SAM (Fig. 2). We attribute the 
60 RU shift to refractive index effects (which are known to 
sensitively affect the SPR response), and the difference of 40 
RU to non-specific binding. Thus, non-specific binding was 
very low, justifying the use of the CD20 scramble as the refer-
ence channel in all subsequent analyses. Moreover, the com-
plete absence of a response (after subtraction of the reference 
channel) for an equal concentration of trastuzumab, a mAb 
which belongs to the same IgG subclass, demonstrates the 
specificity of the CD20 surface for RTX (Fig. 2, orange curve, 
Fig. S4, Fig. S12 in the supporting information). 
 
Figure 2. SPR sensorgrams representing control experiments. 
Raw curves are shown for RTX injections at 1 µM onto SAMs 
with CD20 epitope (blue), with a CD20 scramble (purple), and 
without any peptide functionalization (pure thiol-hydroxyle; 
green). Inset: Zoom into a part of the data. The response on the 
peptide-free surface is caused by refractive index differences 
between the pure and mAb containing solutions, whereas the 
small additional response on the CD20 scramble likely reflects 
minor and transient non-specific (NS) mAb binding. The specific-
ity of CD20 antigen for RTX is evaluated by the injection of 
trastuzumab (1 µM) onto the CD20 flow cell (orange curve ob-
tained after subtraction of CD20 scramble reference data). The 
CD20 and CD20 scramble surfaces were made from functional-
ized SAM (prepared with 20% thiol azide) bearing 56 pmol.cm-2 
peptide. 
SPR binding assays were then carried out to determine the 
kinetic parameters of the RTX-CD20 interaction as a function 
of CD20 surface density. Figure 3 depicts the recorded binding 
response profiles for three different CD20 surface densities. 
The sensorgram shapes along with the magnitude of the equi-
librium responses show a dependence of RTX binding on the 
ligand density in the following rank order: 46 > 2.8 > 85  
pmol.cm-2. Figure 3B shows a saturation for the SPR signal at 
500 nM (2000 RU) while for 2.8 pmol.cm-2 (Fig. 3A) and 85 
pmol.cm-2 (Fig. 3C) the SPR responses did not reach the satu-
ration (1000 RU and 450 RU for 1 µM, respectively). It is 
important to note that for the highest CD20 surface density the 
 
affinity is the lowest. An enhancement of the affinity with the 
increase of the CD20 surface density until reaching a plateau 
was expected. 
The so-called heterogeneous ligand (HL) model was used to 
extract kinetic parameters, i.e. the on-rate (kon) and off-rate 
(koff), from the data (Fig. S6-S7, table S1, in the supporting 
information). This model allows interactions with up to two 
ligand species with distinct kinetic parameters. The deconvo-
lution of the modeled curves revealed that one interaction was 
generally dominant. The second interaction exhibited low 
magnitude, and the shape of the curves (for the second interac-
tion) was characteristic of a non-specific interaction. We hy-
pothesize that the second interaction is related to soluble RTX 
aggregates which can interact with CD20 surface, as self-
association of RTX has been already mentioned in the litera-
ture.27 The fitted data based on the HL model are presented on 
the sensorgrams in figure 3 for the association and dissociation 
phases corresponding to the mAb interaction. The apparent KD 
determined either by using the kinetic data (koff/kon ratio) or by 
a Langmuir binding isotherm plotted from the sensorgrams at 
steady-state equilibrium are similar (Table 2). 
 
Figure 3. RTX-CD20 SPR binding profiles. Sensorgrams were 
recorded at different CD20 surface densities: (A) 2.8 pmol.cm-2, 
(B) 46 pmol.cm-2, and (C) 85 pmol.cm-2. RTX concentrations 
were ranging from 5 to 1000 nM (5, 10, 20, 50, 100, 200, 500 and 
1000 from yellow to orange curves). The sensorgrams were fitted 
with the heterogeneous ligand kinetic model (RI correction = 0) 
and the fitted curves were added to the graph (black curves). 
Figure 4A depicts the evolution of these apparent KD values 
as a function of CD20 surface density. It clearly shows a de-
pendence of the ligand density on the RTX binding affinity. At 
low antigen density (2.1 pmol.cm-2), the KD value is extremely 
high (977 ± 8 nM). When increasing the CD20 densities, the 
KD values decrease until reaching a minimum of 32 nM for a 
surface displaying around 46 pmol.cm-2 of CD20 epitope, 
which appears to be the optimal surface density. Interestingly, 
the apparent maximum response obtained at 46 pmol.cm-2 
CD20 (KD = 32 nM) is close to the values reported from in 
vitro analysis performed by flow cytometry with CD20-
expressing cells (5-19 nM).8,9 Increasing the CD20 epitope 
density beyond 46 pmol.cm-2 to 85 pmol.cm-2, was accompa-
nied by a dramatic increase of KD to values in the micromolar 
range. Such evolution can be rationalized by the influence of 
the average inter-antigen distance on the RTX binding affinity 
on the antigenic surface. Compactness of the CD20 layer is 
expected when the inter-antigen distance decreases. Correlat-
ing with the KD evolution, we observe an inverse variation of 
the maximum SPR responses (Rmax values) as shown the figure 
4B. The maximum binding capacity of RTX is observed for 46 
pmol.cm-2 (corresponding to the minimal KD), whereas Rmax 
values fall down afterwards, meaning that less mAbs interact 
with the surface at high surface density. This result can be 
assigned to the high compactness of the layer due to CD20-
CD20 interaction that makes the CD20 epitope less available 
for RTX binding. 
By using a previously reported model,28,29 we were able to 
estimate the fraction of surface-grafted antigens that is availa-
ble for RTX binding. Based on consideration of antibody size 
and antigen surface density, CD20 epitopes already engaged in 
RTX interaction or effectively obstructed by a surrounding 
RTX were excluded to estimate the fraction of antigens acces-
sible for additional binding (Fig. S13, Eqs. S4-5, in the sup-
porting information). For a CD20 density of 46 pmol.cm-2, 
only 20% of CD20 are available for a subsequent RTX rebind-
ing (Fig. S13 in the supporting information). Under this cir-
cumstance, the Rmax cannot be enhanced further above a graft-
ing density of 50-60 pmol.cm-2. Furthermore, high densities of 
CD20 could generate CD20-CD20 interaction that inhibits the 
binding of mAb.  
In addition to SPR analysis, an apparent binding affinity 
was determined by QCM-D (Table S2, Eq. S6, Fig. S14 in the 
supporting information) from the shift in frequency measured 
for various RTX concentrations on surfaces displaying 2.8, 46 
and 85 pmol.cm-2 of CD20 epitope. As expected, similar re-
sults were observed and a minimal KD was obtained for 46 
pmol.cm-2 (Table S2 in the supporting information). 
Furthermore, KD-related observations can be made for kinet-
ic parameters, especially for kon values that tend to follow 
similar variation. Table 2 shows a 10-fold increase in kon for 
CD20 densities between 2.1 pmol.cm-2 (4.7 × 105 M-1.s-1) and 
23.7 pmol.cm-2 (45.6 × 105 M-1.s-1). This density range corre-
sponds to the growth of available CD20-containing surface 
densities until reaching a plateau corresponding to 46 
pmol.cm-2 (Fig. S7 in the supporting information). Values of 
kon increase with the amount of antigens on the surface, while 
KD values decrease. In contrast, for high CD20 densities (ГCD20 
> 46 pmol.cm-2), the drop in kon is explained by CD20-CD20 
interaction on surface that reduces their accessibility. Such 
results have already been reported in the literature.30 
 
 
Figure 4. Impact of CD20 density on RTX binding affinity. (A) Binding affinity, (B) Rmax measured for RTX (KD and Rmax were deter-
mined by kinetic data). The antigen surface density was calculated with Jung’s formula, starting from the resonance response unit (RU) 
corresponding to the in situ covalent grafting of CD20 epitope to the sensor chips. 

















0.1 2.1 ± 0.4 9.1 ± 0.8 4.7 ± 1.3 0.46 ± 0.02 977 ± 8 694 ± 37 
1 2.8 ± 0.8 7.4 ± 1.2 17.7 ± 7.1 0.46 ± 0.24 248 ± 94 273 ± 72 
2.5 23.7 ± 4.0 2.7 ± 0.2 45.6 ± 6.8 0.35 ± 0.07 75 ± 6 98 ± 9 
12.5 46.1 ± 10.5 2.0 ± 0.2 27.5 ± 9.3 0.08 ± 0.03 32 ± 12 25 ± 12 
20 56.0 ± 13.0 1.8 ± 0.2 17.3 ± 2.2 0.27 ± 0.06 152 ± 16 181 ± 16 
50 84.9 ± 4.9 1.4 ± 0.0 4.4 ± 2.6 0.47 ± 0.32 1007 ± 16 1156 ± 114 
(a) CD20 Surface density on SPR sensor chip determined by Jung’s formula. (b) Root-mean-square distances between two CD20 epitopes 
calculated from the surface densities. 
Concurrently, values of koff decrease significantly with in-
creasing densities until a minimal value (koff = 0.08 s-1) at 46 
pmol.cm-2. For high CD20 densities, values of koff increase to 
about 0.4 s-1 (Table 2). 
All these variations are consistent with a high probability of 
a statistical rebinding of the mAb together with the occurrence 
of potential bivalent binding when CD20 density reaches an 
optimal value with sufficient inter-antigen distance while 
maintaining good accessibility of the antigen (Fig. 5). These 
two phenomena cannot be discriminated using SPR. This 
technique measures the change in the refractive index near the 
surface. The change in refractive index is proportional to the 
total amount of RTX in close proximity to the surface but 
cannot discriminate those which are bound by one arm to 
those bound by two arms. 
The effect of antigen surface density on the binding affinity 
of antibodies has been already reported in the literature, for 
instance for HIV-1 neutralizing antibodies interacting with 
gp120 glycoprotein.31 The data reveal that the extent of the 
changes of the binding energetics as a function of antigen 
density strongly depend on the binding affinity of each anti-
body. The authors observed a marked increase in avidity to 
variation in antigen density in the case of low to moderate 
binding affinity whereas the impact of antigen immobilization 
is very low for antibodies exhibiting high affinity. 
To better understand the gain of affinity due to the statistical 
rebinding and to the bivalency of the mAb, RTX Fab frag-
ments were used for SPR binding assays (Fig. S15, in the 
supporting information). Table 3 shows the kinetic parameters 
obtained for the Fab on surfaces displaying 2.8 and 46 
pmol.cm-2 of CD20. We observe that kon and koff values are 
affected when increasing the CD20 surface density. These 
concomitant variations are supported by the change in accessi-
bility of CD20 epitope which is dependent on the CD20 sur-
face density resulting in a significant increase of KD (12700 vs 
617 nM, for 2.8 and 46 pmol.cm-2 of CD20 respectively). 
Interestingly, the koff value for the Fab (0.64 x 105 M-1.s-1) is 
similar to the one obtained for RTX (0.46 x 105 M-1.s-1) for 
surface displaying 2.8 pmol.cm-2 of CD20. This result suggests 
that statistical rebinding is restricted on surface displaying low 
CD20 density (Figure 5). On the contrary, the rate of associa-
tion for the Fab is around 30-fold lower than for the bivalent 
mAb (0.6 vs 17.7 x 105 M-1.s-1) (See Fig S16, in the supporting 
information). Such discrepancies can be explained by the 
bivalency of the RTX/CD20 interaction and the flexibility of 
the two Fab arms (3-14 nm) that would allow the mAb a wider 
search range for CD20 binding sites compared to Fab. The 
 
enhancement of avidity afforded by the bivalency of RTX is 
more pronounced for a CD20 surface density of 2.8 pmol.cm-2. 
Consequently, kon is greatly affected by these phenomena.  
Such comparison underlines the bivalency effect for the asso-
ciation of RTX when antigen density is low. For surface densi-
ty of 46 pmol.cm-2 of CD20, the koff values for the Fab (0.2 s-1) 
and for the RTX (0.08 s-1) point out the high probability of 
RTX rebinding on CD20 surface. Intrinsic flexibility of the 
mAb allows exploring large surface as the distance between 
both active sites (paratope) varies from 3 to 14 nm.32 Together 
these results show how important is the role of the second arm 
on the RTX binding capacities, as it improves the affinity of 
the mAb for the surface and its statistical rebinding (Figure 5). 
Regarding the KD values, a strong difference is observed for 
2.8 pmol.cm-2 (KD = 12700 nM for Fab vs KD = 248 nM for 
RTX) and, to a lesser extent, for 46 pmol.cm-2 (KD = 617 nM 
for Fab vs KD = 32 nM for RTX), leading to Fab/RTX KD 
ratios of 51 and 19 respectively.  These data are in accordance 
with values from the literature. Whitesides et al. reported a 50-
fold enhancement of binding for a synthetic bivalent protein 
dimer (mimicking mAb) compared to the monovalent one 
interacting with mixed SAMs presenting ligands.33 It is worth 
noting that the contribution of the surface densities can be 
isolated by comparing the KD values related to RTX Fab - 
CD20 interaction at 2 and 46 pmol.cm-2. It turns out that a 21-
fold factor is observed from low to medium antigen grafting 
density. As RTX Fab is a monovalent molecule, improvement 
of affinity is exclusively due to surface densities, improving 
the rate of association, and the rate of dissociation via rebind-
ing process. We have to underline that this phenomenon also 
exists for the mAb-CD20 recognition but to a lesser extent, 7-
fold factor (KD = 248 nM for density of 2.8 pmol.cm-2 vs 32 
nM for 46.1 pmol.cm-2). This result confirms that the contribu-
tion of bivalency is critical for both the mAb association, but 
also for the statistical rebinding.  The rebinding process was 
described by Preiner et al. as a stochastic walking of IgGs on 
2D rigid surfaces.34 The authors demonstrated by high speed 
atomic force microscopy that the moving speeds and step sizes 
are dependent of the antigen density. 













1 2.8 ± 0.8 0.6 ± 0.2 0.64 ± 0.12 12700 ± 3750 
12.5 46.1 ± 10.5 3.8 ± 0.8 0.2 ± 0.02 617 ± 74 
(a) CD20 Surface density on SPR sensor chip determined by 
Jung’s formula. 
To date, there is evidence supporting the impact of CD20 
distribution on the clinical efficacies of RTX.6,7,35 Antigen 
density is a critical parameter that determines the biological 
efficacy of the mAb especially via the complement-induced 
cell death. Additionally, microscopy experiments of fluores-
cent RTX showed a heterogeneous distribution of CD20 anti-
gens on the cell surface,8 suggesting that CD20 proteins are 
organized into clusters.36 In our study, the highest affinity was 
determined for a CD20 surface density of 46 pmol.cm-2 which 
corresponds to an average inter-antigen spacing of around 2 
nm (Table 2). Considering the size of CD20-expressing B cells 
(around 8 μm in diameter) and the amount of CD20 antigens 
per cells (2 to 6 × 105),5,8,37 a homogeneous distribution would 
imply areal mass densities of 0.003 to 0.6 pmol.cm-2. Accord-
ing to our SPR experiments, these values (average inter-
antigen spacing above 7 nm) correspond to surfaces that did 
not allow strong RTX binding (Fig. 5, Table 2). Together, our 
results provide strong evidence for a nanoscale distribution of 
CD20 and the requirement of an average critical inter-antigen 
spacing of 2 nm for RTX binding. We suggest that this critical 
CD20 density is required within CD20 clusters on cell surface 
for efficient RTX binding. 
 
Figure 5. Schematic of rebinding phenomena occurring on sur-
faces displaying CD20 surface densities during the rinsing step: 
(A) low, (B) medium, (C) high CD20 surface densities. At low 
and high antigen surface density, the antibody is mostly bound 
through one arm like the Fab, and is quickly removed from the 
surface (A and C). At medium antigen surface density (46 
pmol.cm-2), the probability of the mAb to bind with the two arms 
and to find a neighboring antigen after dissociation of one of its 
arm is high, leading to a lower koff, and so a stronger avidity. 
In this study, we designed surfaces with tunable areal mass 
densities of the CD20 epitope. We were able to study the 
contribution of the statistical rebinding and the bivalent effect 
of RTX mAb, especially through a comparison with the RTX 
Fab. An average critical inter-CD20 spacing of nearly 2 nm 
was found that confers the best conditions for RTX binding. 
This nanoscale distribution corroborates the prerequisite CD20 
cluster formation for biological activity of RTX. It is expected 
that this inter-antigen spacing might be required for other 
mAbs as well. Additionally, we reason that the design of such 
surfaces will pave the way for the discovery of mAb mimics, 
especially through the screening of peptides, nucleic acid 
aptamers or phage libraries. 
Detailed description on the CD20 epitope synthesis (HPLC and 
mass analysis) and additional SPR sensorgrams and QCM-D 
profiles were available in the supporting information. The Sup-
porting Information is available free of charge on the ACS Publi-
cations website. 
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 General procedure for CD20 synthesis 1.
 
1.1. Reagents and material 
All Fmoc amino acid derivatives and resins were purchased from Advanced ChemTech Europe (Brussels, Belgium), Bachem Bio-
chimie SARL (Voisins-Les-Bretonneux, France) and France Biochem S.A. (Meudon, France). Other reagents were obtained from 
Aldrich (Saint Quentin Fallavier, France) or Acros (Noisy-Le-Grand, France). RP-UHPLC analyses were performed on Waters 
equipment consisting of a Waters Acquity H-Class Bio UPLC combined to a Waters SQ Detector 2 mass spectrometer. The analyt-
ical column used was a ACQUITY UPLC BEH C18 Column, 130Å, 1.7 μm, 2.1 mm x 50 mm operated at 0.6 mL/min with linear 
gradient programs in 2.20 min run time (routine program: 5% to 100 % B in 2.20 min). UV monitoring was performed at 214 nm. 
Solvent A consisted of H2O containing 0.1% trifluoroacetic acid (TFA) and solvent B consisted of CH3CN containing 0.1% TFA. 
Water was of Milli-Q quality. CH3CN and TFA were LC-MS grade. RP-HPLC purifications were performed on Gilson GX-281 or 
GX-281. The preparative column, Macherey-Nagel 100 Å 7 µm C18 particles, 250 × 21 mm was operated at 20.84 mL/min. Sol-
vents A and B were the same as the ones used in RP-HPLC analysis.  
 
1.2. Synthesis of CD20 
 
 
Synthesis of the protected peptide was carried out using the Fmoc/t-Bu strategy.  For both peptides, the first amino-acid was manu-
ally attached on a 2-chlorotritylchloride® resin (loading ≈ 0.5 mmol/g). Peptides were then elongated on a peptide synthesizer. 
Coupling reactions were performed by using 4 eq. of N-Fmoc-protected amino acid (relative to the resin loading) activated in situ 
with 2 equiv. of  HBTU and 3-5 eq. of diisopropylethylamine (DIPEA) in DMF (10 mL/g resin) for 30 min. N-Fmoc protecting 
groups were removed by treatment with a piperidine/DMF solution (1:4) for 10 min (10 mL/g resin). The alkyne function was then 
manually added on N-terminus by a coupling reaction with 4-Pentynoic acid (2 equiv.). The linear peptides were then released from 
the resin by treatments with a solution of trifluoroacetic acid/trisisopropylsilane/H2O/2,2′-(Ethylenedioxy)diethanethiol 
(92.5/2.5/2.5/2.5, 10 mL/mg resin, 1 h). With this treatment, all protecting group of the peptides are removed. After evaporation, 
diethyl ether was added to precipitate peptides. They were then triturated and washed three times with diethyl ether to obtain crude 
materials. 
 
1.3. Disulfide bond formation 
 
 
Disulfide bonds were formed by diluting peptides to 500 µM in Tris buffer 0.1 M, guanidine 20 mM, and DMSO 5% (v:v) and 
maintaining oxidative conditions for 48 h. Disulfide bond formation was checked by RP-UHPLC analyses. 
 









ESI analysis of CD20: 
MS (ESI-MS, positive mode): C126H183N33O44S2 Calcd : MW = 2928.264 g.mol











 SPR quantification of grafted peptide 2.
 
2.1. Jung’s formula 
Surface Plasmon resonance (SPR) is an optical sensing technique which, similar to SE, is sensitive to changes in refractive index. 
We considered here a multilayer structure with the first layer SAM used to subsequently attach CD20 epitope considered as a se-
cond layer that has been monitored by SPR. The Jung’s formula 1 combined with the De Feijter’s equation (Eq. S1) allowed the 
conversion of the magnitude of the response units measured during the chemical coupling (conventionally expressed in RU) into 


















     (Eq. S1) 
 
where RU is the number of resonance units gained by the peptide grafting, d’ is the thickness of the peptide film (d’ = 4.6 nm, as 
determined by SE), d is the thickness of the SAM (d = 2.5 nm, as determined by SE), dn/dc is the refractive index increment (dn/dc 
= 527 cm3.mol-1 which corresponds to 0.18 x 2928 for CD20), and dp is the evanescent wave depth (dp = 175 nm).3 
This expression requires knowledge of SAM and CD20 layer thicknesses. The SPR response would be the same as that of the sim-






  due to the 
SAM underlayer. As the thickness of the SAM is very thin compared to the penetration depth (2.5 nm versus 175 nm), this factor is 
close to 1 and the response due to the attachment of the CD20 layer is unaffected by the presence of SAM layer between the metal 
and the CD20 layer. 
 
2.2. SPR determination of CD20 epitope density 
 
 
Figure S1. Determination of the number of resonance response units gained by the peptide grafting. The large change of refractive index 
during the injection of DMSO prevents the grafting to be monitoring in real-time. Therefore, the quantity of antigen immobilized on the 
surface is evaluated from the shift in resonance units after rinsing as compared to before peptide injection (∆RU in the inset). On this ex-
ample, the peptide was injected at 2 µl.min-1 for 480 s on a 20%-N3 functionalized surface.  





















































2.3. Correlation between the molar fraction of thiol-azide in the solution from which the SAMs were 
formed and the CD20 surface density. 
 
 
Figure S2. CD20 surface density (measured by the Jung’s formula from SPR in-situ grafting) as a function of the molar fraction of N3-
terminated thiol in the thiol mixture used to prepare the SAMs. 
Figure S2 shows that above 50% of thiol-azide CD20 surface density reached saturation. This observation could be explained 
by the size of CD20 (width max: 1.5 nm;  length: 2.5 nm (non-stretched)). The theoretical saturation could be calculated 









 Optimization of SPR binding assays: Impact of buffer nature 3.
 
The effect of buffer type on RTX binding to CD20 was studied since the rituximab is stored in an injectable rituximab solution 
(MabThera solution) that differs from the buffers we use routinely for SPR experiments. Binding assays were performed and com-
pared in three buffer conditions (MabThera buffer, PBS buffer, or HEPES buffer) on the same surface. As can be seen on Figure 
S3, conventional buffers such as PBS or HEPES provided a better interaction. Consequently, we choose to work with PBS buffer 
after verifying the absence of dilution effect of MabThera buffer for the observed concentration range. A solution of 1 µM was 




Figure S3. Binding assays performed by injecting rituximab antibody in different buffers. (A) in MabThera® Buffer = 154 mM NaCl, 25 
mM citrate, 0.066% P80; (B) in PBS, 3 mM citrate, 0.005% P80; (C) in 10 mM Hepes, 150 mM NaCl, 3 mM citrate, 0.005% P80. Concen-
tration range is: 10, 20, 50, 100, 200, 500, 1000 nM. These experiments were performed on the same surface functionalized with the ex-







 Specificity of CD20-functionalized surface toward RTX binding. 4.
 
The graph below shows that trastuzumab (a mAb which belongs to the same IgG subclass) binds the CD20 functionalized surface 
in the same manner than on the CD20 scramble surface whatever the CD20 surface density.  
 
           
A       B 
Figure S4. Overlapping of the sensorgrams characterizing the binding of trastuzumab (100 nM) on two different flow cells (Fc): Fc1 (red 
curve) CD20 scramble-functionalized surface, Fc2 (green curve) CD20-functionalized surface and Fc3 (blue curve) N3-terminated SAM 
surface. Surface densities of CD20 or CD20 scramble functionalized surfaces correcpond to (A) 46 pmol.cm-2 (Fc1 and Fc2) and (B) 2.8 
pmol.cm-2 (Fc1 and Fc2) and 0 pmol.cm-2 (Fc3). 






































































  Stability of the surface over time 5.
 
CD20-coated SPR sensor chips were typically used for a large numbers of binding assays, each followed by a regeneration step. To 
confirm the stability of the CD20 coating over time, a standardized binding assay with 1 µM rituximab was performed at regular 
intervals. Figure S3 shows the responses corresponding to rituximab binding on a freshly prepared surface (black curve; Rmax = 
2550 RU), after 76 regeneration steps (purple curve; 2400 RU, or 94% of the initial response), and after 140 regeneration steps 
(blue curve; 2265 RU, or 89% of the initial response). These results confirm that the surface is stable over time, and that the loss of 
ligand activity was negligibly small over the duration of a binding assay. 
 
 
Figure S5. SPR signals obtained for a 1 µM rituximab injection on the same surface at different wear stages: freshly prepared surface 
(black), after 76 regeneration steps (purple), after 140 regeneration steps (blue). A regeneration step consist of an injection of Glycine/HCl 





























 Choice of the SPR model 6.
 
The SPR data were fitted using a heterogeneous ligand (HL) model. The SPR response can be considered as a result of the contribu-
tion of two different independent interactions. One example of the deconvolution of the modelled signal is shown in figure S4. It 
appears that the two interactions exhibit very different magnitude, the second one is very weak and the curve shape is characteristic 
of a non-specific interaction with a continuous positive drift during the association phase without apparent dissociation phase. For 
the HL model, the data evaluation software provides two association rate constants, kon1 and kon2, and two dissociation rate con-
stants, koff1 and koff2, as well as two theoretical maximal responses, Rmax1 and Rmax2. These sets of parameters consist of the specific 
interaction (1st interaction in Figure S6; typically representing between 80 and 90% of the total SPR signal, see Figure S7A) and a 
non-specific interaction (2nd interaction in Fig. S6; representing the remaining signal of less than 20% in most cases). Consequently, 
the data presented in the manuscript are only related to the specific first interaction.  
 
Figure S6. RTX-CD20 SPR binding profile obtained at 85 pmol.cm-2 of CD20 surface density. RTX concentrations were 5, 10, 20, 50, 
100, 200, 500 and 1000 nM. The sensorgrams were fitted with the heterogeneous ligand kinetic model and the fitted curves were added to 
the graph (black curves). Insert: Signal deconvolution of the curve corresponding to the RTX injection of 500 nM. The observed sensor-
gram (pink) is composed of signal contributions of the specific interaction (1st interaction – blue curve) and a non-specific interaction (2nd 
interaction – red curve). Bulk and drift (=0) is represented by the green curve. By using the heterogeneous ligand model, we assume that 
each curve can be divided into two contributions. The experimental response (pink curve) is composed of a large SPR signal having the 
shape of a specific binding (1st interaction – blue curve) and a second weak SPR signal whose shape is characteristic of a non-specific 
binding (2nd interaction – red curve).  
For the example presented in Figure S5, the numeric contribution of each interaction is given by the fitted Rmax values (Table S1). 
With Rmax1 = 804 and Rmax2 = 127 RU, the interaction associated to the blue curve represents 84 % of the SPR response, and 
strengthens the idea that this corresponds to the specific interaction. 
 
Table S1. Parameters of the CD20/RTX interaction obtained after curve fitting. The heterogeneous ligand model provides two sets 
of data corresponding to interaction 1 (blue curve) and interaction 2 (red curve). 
kon1 (1/Ms) koff1 (1/s) KD1 (M) Rmax1 (RU) kon2 (1/Ms) koff2 (1/s) KD2 (M) Rmax2 (RU) RI (RU) χ² (RU²) 
6.72E+05 0.7668 1.14E-06 804 8263 0.003825 4.63E-07 127 0 7.66 
 
Normalized maximal responses Rmax of the two interactions are presented in Figure S7A. It shows that the signal magnitude of the 
second interaction is in the minority (in most cases, it represents less than 20% of the total signal magnitude). The association rate 
constants kon for the two interactions as a function of CD20 surface coverage are shown in Figure S5B. kon values related to the 
second interaction are typically much smaller than for the first interaction, and the variation in kon2 is low across the full range of 








   A 
 
 
    B 
Figure S7. (A) Normalized Rmax (for the two interactions extracted from HL model, Rmax1: black square, Rmax2: red disk; normalized such 
that Rmax1 + Rmax2 = 1) as a function CD20 surface coverage. (B) Association rate constants (for the two interactions extracted from HL 
model, kon1: black square, kon2: red dot). 
As the shape of the curves of the second interaction (figure S6 - insert) is characteristic of a non-specific interaction, we hypothe-
size that the second interaction is related to soluble RTX aggregates which can interact with the CD20 surface. This interpretation is 
reinforced by the variation of the normalized Rmax with the CD20 density which is increasing for low CD20 densities (between 0 
and 10 pmol.cm-2). Self-association of RTX has been already mentioned in the literature and shown by using chromatography of 
exclusion.4 




















 Spectroscopic Ellipsometry (SE) experiments 8.
 
Spectroscopic ellipsometry (SE) monitors the changes in ellipsometric angles ψ and Δ of polarized light upon reflection at a planar 
surface. SE is sensitive to changes in refractive index of the film and, by proper data treatment, provides access to the film refrac-
tive index and thickness, as well as the adsorbate surface density. 
Experiments by QCM-D coupled with spectroscopic ellipsometry were performed in situ at a working temperature of 23 °C using a 
custom-designed open glass cuvette.1 SAMs were formed on gold-coated QCM-D sensors using the same procedure as in QCM-D 
experiments. SE data were acquired with a spectroscopic rotating compensator ellipsometer (M2000V; J. A. Woollam, Lincoln, 
NE, USA) over a wavelength range of λ = 380-1000 nm, at 65° of angle of incidence. Before use, the inner surfaces of the glass 
cuvette were passivated by exposure to an aqueous solution of 10 mg.mL-1 of bovine serum albumin for 10 min, rinsed with water 
and blow-dried with nitrogen gas. Before each experiment, measurements of the ellipsometric angles Δ and Ψ were performed on 
the SAM-coated surface in three distinct conditions: in air without any cuvette, in air with the sensor installed in the cuvette, and 
finally with the cuvette filled with ultrapure water. These steps are important to characterize SAM properties, and also to check for 
negligible window effects (as described in ref. 1). In situ measurements of the peptide grafting process consisted of obtaining a 
stable baseline in DMSO:H2O (1:1) for a few minutes, injection of CD20 click solution at the desired final concentration, and rins-
ing in DMSO:H2O (1:1) solution. During all steps, the cuvette content was continuously homogenised with the aid of a magnetic 
stirrer. For the rinsing step, the cuvette content was diluted by repeated addition of fresh DMSO:H2O (1:1) solution and removal of 
excess liquid using a syringe needle connected to a peristaltic pump (Ismatec, Glattbrugg, Switzerland). The same procedure was 
performed to finally finish in water at pH 8. 
The thickness and the refractive index of the layers (SAM and CD20) were determined through fitting of the data to optical models, 
using the software CompleteEASE (Woollam). The model relates the measured Δ and ψ as a function of λ to the optical properties 
of the sensor surface, the adsorbed film, and the surrounding solution. The semi-infinite bulk solution was treated as a transparent 
Cauchy medium, with a refractive index nsol(λ) = Asol + Bsol/λ2. For pure water as bulk solution, Asol = 1.322 and Bsol = 0.00322 
μm2 were used. Toward determination of the thickness of the CD20 layer, the opaque gold coating modified with SAM was treated 
as a homogeneous substrate. Its effective optical properties were determined from data acquired in the presence of bulk solution 
(pure water) but in the absence of a protein film, by fitting the refractive index and extinction coefficient over the accessible λ range 
using a B-spline algorithm implemented in CompleteEASE. The solvated CD20 layer was treated as a single layer, which we as-
sumed to be transparent and homogeneous (Cauchy medium), with a given thickness d and refractive index n(λ) = A + B/λ2. Fitting 
was performed in pure water with d and A as fitting parameters, assuming B = Bsol. The χ2 value for the best fit was typically 
below 2, indicating a good fit. The best fit gave a CD20 layer thickness of 4.6 ± 0.2 nm and a refractive index of 1.42 ± 0.02 (for λ 
= 632.8 nm). 
The thickness of the SAM was extracted using SE analysis in air. To this end, the surface was characterized before and after SAM 
formation. The optical properties of the gold coating were determined from data acquired prior to SAM formation, by fitting the 
refractive index and extinction coefficient over the accessible λ range using a B-spline algorithm. The SAM was treated as a Cau-






 QCM-D quantification of grafted peptide 9.
 
Quartz crystal microbalance (QCM-D) monitors the changes in resonance frequency, Δf, and energy dissipation, ΔD, of the shear 
oscillation of a quartz crystal sensor upon binding and unbinding processes on the sensor surface. To a first approximation, Δf is 
related to the amount of bound material (including hydrodynamically coupled solvent) and ΔD is related to the softness of the inter-
facial film. In the case of homogeneous, quasi-rigid films the frequency shift is proportional to the mass uptake per unit area 
(mQCM), as described by the Sauerbrey:  
 
fCmQCM               (Eq. S2) 
 
Here, the mass sensitivity constant, C, is equal to 18.06 ng.cm-2.Hz-1 for sensors with a fundamental resonance frequency of f1 = 
4.95 MHz. The areal mass density includes water hydrodynamically coupled to the organic film.  
 
 
Figure S9. Example of a QCM-D profile recorded during the covalent grafting of CD20 epitope onto a SAM-azide functionalized surface 
prepared from a thiol mixture containing 12.5% of azide-terminated thiols. Black line: frequency shift; red line: dissipation shift. The 
duration of peptide grafting, and of the subsequent rinsing step, are indicated by arrows on top of the graph. A partial increase in frequency 
(and decrease in dissipation) is obtained when the surface is washed with the rinsing solution due to differences in the density and/or vis-
cosity of the rinsing solution compared to the peptide grafting solution, and possibly also due to release of non-specifically bound reagents. 
The QCM-D signals after rinsing confirm the stability of the surface. 
 









































As expected, for a surface without azide function no measurable shift in frequency was detected when comparing before and after 
incubation with the CD20 antigen, signifying that there is no stable yet unspecific peptide adsorption on the surface (Fig. S7). 
Changes in frequency during incubation with the peptide solution are likely due to solution effects. The higher rate of change in 
frequency recorded during the rinsing step (compared to that of the injection step) is due to a variation of the flow rate, 5 µL/min 








 Calculation of the CD20 hydration layer 10.
 
The hydration H of the CD20 layer is deduced from equation S3: 
 
H = (mQCM - mSPR) × 100/mQCM  (Eq. S3) 
 
with mSPR the optical mass (determined by Jung’s formula; Eq. S1) and mQCM the acoustic mass (determined with Sauerbrey’s 
equation; Eq. S2). 
  





























 Specificity of CD20 functionalized surface towards RTX binding – QCM-D experiment 11.
 
 
Figure S11. QCM-D profiles characterizing CD20 – RTX recognition. 10 nM RTX in phosphate buffered saline (PBS) with 3 mM citrate 
and 0.005% P80 was injected on 20% azide-functionalized surfaces that display CD20 (solid line) and CD20 scramble (dashed line). T = 
25°C, flow rate = 10 µL.min-1. 
 
 
 A       B 
Figure S12. QCM-D profiles characterizing the specific recognition of RTX. (A) CD20 functionalized surface and (B) N3-terminated 
SAM surface prepared from a thiol solution containing 10% of N3-terminated thiol, first injection of 1µM Herceptin and second injection 






 Calculation of the available CD20 antigens on SAM substrate 12.
 
Considering the organization of the surface, it is unlikely that all CD20 antigens grafted to the surface can be fully implicated in 
RTX binding. Yang et al 5 have developed a model (adapted from a previous model reported by Hlavacek et al 6 characterizing the 
surface association in bivalent systems) with the objective of calculating the available ligand density for subsequent mAb binding to 
an antigen functionalized surface. According to this model some ligands may be available, whereas others are already bound in 
another interaction, or unavailable because they are covered by an analyte, or because a neighboring ligand obstructs binding. The 
probability of a ligand being available for binding can be expressed as the product of: (1) the probability that a ligand is not  bound 
to a surface adsorbed mAb, (2) the probability that an unbound ligand is not covered by the mAb and (3) the probability that an 
unbound and uncovered ligand is not excluded from binding by its close proximity to a surface bound mAb.6 
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Figure S13. (A) Possible states that can be adopted by CD20 antigens on a surface; (B) Visualization of the percentage of available anti-
gens. 
The calculation of available CD20 is based on this model, where the authors calculated the probability of a ligand being available 
for binding when i sites are already bound. The fraction of bound sites is i/n, where n is the total number of sites. The number of i 



















 (Eq. S4) 
where a is the area covered by an IgG antibody (60 nm2), and n/A the density of grafted CD20 antigen calculated from SPR exper-
iments. 








     (Eq. S5) 
The results show that almost all CD20 are available (81%) for 1% of azide (ГCD20 = 2.8 pmol.cm-2), but only 21% are available for 





 Determination of the binding affinity using QCM-D 13.
 
The variation of KD as a function of CD20 surface densities has also been evaluated by QCM-D. To this end, RTX-CD20 binding 
assays were performed by QCM-D for three different azide-functionalized SAMs: 2.5, 12.5, and 50%. RTX concentrations used 
are: 
For 2.5% thiol-azide: 10, 25, 50, 100, 250, 500, 1000, 2000 nM 
For 12.5% thiol-azide: 5, 10, 50, 100, 250, 500, 1000, 2000 nM 
For 50% thiol-azide: 0.05, 0.1, 0.5, 1, 2, 4, 6, 9 µM 
For each RTX concentration the frequency shifts at equilibrium were plotted as a function of RTX concentration and the resulting 










    (Eq. S6) 














Figure S14. Example of the Langmuir isotherm obtained for the 2.5% functionalized surface. 
Table S2.  Comparison of CD20-RTX KD obtained from QCM-D or SPR. 
 % N3 
 KD QCM-D 
 (nM) 
 KD SPR 
 (nM) 
 2.5  68.7 ± 6.8  75 ± 6 
 12.5  17.9 ± 3.4  32 ± 12 
 50  13049 ± 1372.9  1007 ± 16 
 
As we can see in Table S2, values found in QCM-D and SPR are in the same order of magnitude in the case of surfaces with 2.5 
and 12.5% of azide functions. However, the gap is more pronounced at 50%, where the KD calculated in QCM-D is much higher 
(out of the concentrations injected).  The trend is though still the same; and in both cases, affinity ranking is identical: KD (12.5%) > 





 Fab binding assays 14.
  
Fab binding assays were performed in the same conditions as for RTX. Fig. S15 illustrates two sets of sensorgrams obtained for 




Figure S15.  RTX Fab - CD20 SPR binding profiles. Sensorgrams were recorded at different CD20 surface densities: (A) 2.8 pmol.cm-2, 
and (B) 46 pmol.cm-2. The Fab fragment concentrations were 50, 200, 500, 1000 nM for 2.8 pmol.cm-2, and from 50, 100, 200, 500, 1000 
nM for 46 pmol.cm-2. The sensorgrams were fitted with the heterogeneous ligand kinetic model (RI correction = 0) and the fitted curves 
were added to the graph (black curves). 
 
  
(A) RTX Fab-CD20 SPR binding profiles (colored curves), black 
curves are the fitted curves (heterogeneous ligand kinetic model: 
ka= 0.5 10
5 M-1.s-1) 
(B) RTX-CD20 SPR binding profiles (colored curves), black curves 
are the fitted curves (heterogeneous ligand kinetic model: ka=18.5 
105 M-1s-1) 
Figure S16. Examples of sensorgrams recorded on the same CD20 functionalized sensor chip bearing 2.8 pmol.cm-2 (prepared from thiol 
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